Gottlieb Highlights Drawback To Increasing US FDA Salaries: Resource Disparity
Commissioner tells agency stakeholders that there could be intra-agency moves to centers and offices that can offer higher pay.
You may also be interested in...
Acting commissioner says greater flexibility in hiring has 'a real potential to solve some of our problems,' although only about 40-50 people have been added to date; recruitment and retention were very much on the minds of the FDA’s leadership at the recent BIO annual meeting, where center directors spoke of the long-term damage caused by the five-week partial government shutdown.
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).
US agency ranks 32nd out of 150 agency subcomponents in annual survey of employees.